Items Tagged ‘HER2’

March 24th, 2015

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer

By

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 […]

View full entry

Tags: Breast Cancer, HER2, herceptin, lapatinib, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, trastuzumab, Tykerb


December 18th, 2014

Breast Cancer Patients Are Now Living Longer without Relapse

By

Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical Oncology. Cancer is considered relapsed when disease returns after it has been in remission following treatment, meaning that signs and symptoms have disappeared. Preventing relapse—or […]

View full entry

Tags: Breast Cancer, cancer, HER2, News, recurrence, Recurrent Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


December 15th, 2014

Neratinib Continues to Show Activity in HER2-Positive Breast Cancer

By

Interim results from an ongoing Phase II clinical trial of neratinib were presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). Neratinib is an investigational, oral medication that targets HER2 as well as HER4 and the epidermal growth factor receptor (EGFR). Twenty to 25 percent of breast cancers overexpress (make too much of) a […]

View full entry

Tags: Breast Cancer, HER2, Metastatic Breast Cancer, neratinib, News, Recurrent Breast Cancer


October 9th, 2014

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By

According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] HER2 is a protein involved in normal cell […]

View full entry

Tags: Breast Cancer, HER2, herceptin, Metastatic Breast Cancer, News, perjeta, Recurrent Breast Cancer


September 16th, 2014

Vaccine Derived from HER2 Protein May Help Prevent Breast Cancer Recurrence

By

A new breast cancer vaccine that is derived from the HER2 protein may help prevent recurrence in patients with HER2-positive disease and appears safe. Phase II study results of the vaccine were released at the 2014 Breast Cancer Symposium, September 4–6, in San Francisco. The HER2 protein, also known as human epidermal growth factor receptor 2, […]

View full entry

Tags: Breast Cancer, GP2, HER2, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, vaccine


June 10th, 2014

Tykerb and Herceptin Combination Therapy Fails to Improve Outcomes for Early Stage HER2 Breast Cancer

By

Dr. Martine Piccart-Gebhart presented results at the 2014 annual meeting of the American Society of Clinical Oncology showing that a combination treatment of Tykerb® (lapatinib) and Herceptin® (trastuzumab) offered no benefit in outcomes for early stage HER2-positive breast cancer patients. Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, HER2, herceptin, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Tykerb